References

1. Vanderschuren, L. J. and Kalivas, P. W. (2000) Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology 151, 99-120.

2. Parsons, C. G., Danysz, W., and Quack, G. (1998) Glutamate in CNS disorders as a target for drug development: An update. Drug News Perspect. 11, 523-569.

3. Witkin, J. M. (1995) Role of N-methyl-d-aspartate receptors in behavior and behavioral effects of drugs, in CNS Neurotransmitters and Neuromodulators, Volume 1: Glutamate (Stone, T. W., ed.), CRC P, Boca Raton, FL., pp. 323-350.

4 Rogawski, M. A. (1996) Epilepsy, in Neurotherapeutics: Emerging Strategies (Pullan, L. and Patel, J., eds.) Humana P, Totowa, NJ, pp. 193-273.

5. Brauner-Osborne, H., Egebjerg, J., Nielsen, E. 0., Madsen, U., and Krogsgaard-Larsen, P. (2000). Ligands for glutamate receptors: design and therapeutic prospects. J. Med. Chem. 43, 2609-2645.

6. MacDonald, J. F., Bartlett, M. C., Mody, I., Pahapill, P., Reynolds, J. N., Salter, M. W., et al. (1991) Actions of ketamine, phencyclidine and MK-801 on NMDA receptor currents in cultured mouse hippocampal neurones. J. Physiol. 432, 483-508.

7. Dingledine, R., Borges, K., Bowie, D., and Traynelis, S. F. (1999) The glutamate receptor ion channels. Pharmacol. Rev. 51, 7-61.

8. Rogawski, M. A. (2000) Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents—toward an understanding of their favorable tolerability. Amino Acids 19,133-149.

9. Maurice, T., Vignon, J., Kamenka, J. M., and Chicheportiche, R. D. (1991) Differential interaction of phencyclidine-like drugs with the dopamine uptake complex in vivo. J. Neurochem. 56, 553-559.

10. Rothman, R. B. (1994) PCP site 2: a high affinity MK-801-insensitive phencyclidine binding site. Neurotoxicol. Teratol. 16, 343-353.

11. ffrench-Mullen, J. M. H. and Rogawski, M. A. (1989) Interaction of phencyclidine with voltage-dependent potassium channels in cultured rat hippocampal neurons: comparison with block of the NMDA receptor-ionophore complex. J. Neurosci. 9, 4051-4061.

12. Wong, E. H. G., Knight, A. R., and Woodruff, G. N. (1988) [3H]MK-801 labels a site on the N-methyl-d-aspartate receptor complex in rat brain membranes. J. Neurochem. 50, 274-281.

13. Witkin, J. M., Gasior, M., Heifets, B., and Tortella, F. C. (1999) Anticonvulsant efficacy of N-methyl-d-aspartate antagonists against convulsions induced by cocaine. J. Pharmacol. Exp. Ther. 289, 703-711.

14. Ginski, M. and Witkin, J. M. (1994) Sensitive and rapid behavioral differentiation of N-methyl-d-aspartate receptor antagonists. Psychopharmacology 114, 573-582.

15. Tricklebank, M. D., Singh, L., Oles, R. J., Preston, C., and Iversen, S. D. (1989) The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor. Eur. J. Pharmacol. 167, 127-135.

16. Koek, W. and Colpaert, F. C. (1990) Selective blockade of N-methyl-d-aspartate (NMDA)-induced convulsions by the NMDA antagonists and putative glycine antagonists: relationships with phencyclidine-like behavioral effects. J. Pharmacol. Exp. Ther. 252, 349-357.

17. Balster R. L. and Willetts, J. (1988) Receptor mediation of the discriminative stimulus properties of phencyclidine and sigma-opioid agonists, in Psychopharmacology: Transduction Mechanisms of Drug Stimuli, (Colpaert, F. C. and Balster, R. L., eds.), Springer-Verlag Berlin, pp. 122-135.

18. Grant, K. A., Colombo, G., Grant, J., and Rogawski, M. A. (1996) Dizocilpine-like discriminative stimulus effects of low-affinity uncompetitive NMDA antagonists. Neuropharmacology 35, 1709-1719.

19. Geter-Douglass, B. and Witkin, J. M. (1997) Dizocilpine-like discriminative stimulus effects of competitive NMDA receptor antagonists in mice. Psychopharmacology 133, 43-50.

20. Troupin, A. S., Mendius, J. R., Cheng, F., and Risinger, M. W. (1986) MK-801, in New Anticonvulsant Drugs (Meldrum, B. and Porter, R. J., eds.), Libey, London, pp. 191-201.

21. Krystal, J. H., Karper, L. P., Seibyl, J. P., Freeman, G. K., Delaney, R., Bremner, J. D. et al. (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51, 199-214.

22. Olney, J. W., Labruyere, J., Wang, G., Wozniak, D. F., Price, M. T., and Sesma, M. A. (1991) NMDA antagonist neurotoxicity: mechanism and prevention. Science 254, 1515-1518.

23. Fix, A. S., Horn, J. W., Wightman, K. A., Johnson, C. A., Long, G. G., Storts, R. W., et al. (1993) Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-d-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex. Exp. Neurol. 123, 204-215.

24. Palmer, G.C . and Wiszowski, D. (2000) Low affinity use-dependent NMDA receptor antagonists show promise for clinical development. Amino Acids 19, 151-155.

25. Rogawski, M. A. (1993) Therapeutic potential of excitatory amino acid antagonists:channel blockers and 2,3-benzodi-azepines. Trends Pharmacol. Sci. 14, 325-331

26. Parsons, C. G., Quack, G., Bresink, I., Baran, L., Przegalinski, E., Kostowski, W., et al, (1995) Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34, 1239-1258.

27. Bubser, M., Zadow, B., Kronthaler, U. O., Felsheim, U., Ruckert, G. H., and Schmidt, W. J. (1997) Behavioural pharmacology of the non-competitive NMDA antagonists dextrorphan and ADCI: relations between locomotor stimulation, anti-cataleptic potential and forebrain dopamine metabolism. Naunyn-Schmiedeberg'sArch. Pharmacol. 355, 767-773.

28. Grant, K. A., Snell, L. D., Rogawski, M. A., Thurkauf, A., and Tabakoff, B. (1992) Comparison of the effects of the uncompetitive N-methyl-d-aspartate antagonist (±)-5-aminocarbonyl-10,11-dihydro-5ff-dibenzo[a,d]cyclohepten-5,10-imine (ADCI) with its structural analogs dizocilpine (MK-801) and carbamazepine on ethanol withdrawal seizures. J. Pharmacol. Exp. Ther. 269, 1017-1022.

29. Geter-Douglass, B. and Witkin, J. M. (1999) Behavioral effects and anticonvulsant efficacies of low affinity, uncompetitive NMDA antagonists in mice. Psychopharmacology 146, 280-289.

30. Sanger, D. J., Terry, P., and Katz, J. L. (1992) Memantine has phencyclidine-like but not cocaine-like discriminative stimulus effects in rats. Behav. Pharmacol. 3, 265-268.

31. Danysz, W., Parsons, G. G., Kornhuber, J., Schmidt, W. J., and Quack, G. (1997) Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies. Neurosci-Biobehav. Rev. 21, 455-468.

32. Ditzler, K. (1991) Efficacy and tolerability of memantine in patients with dementia syndrome Arzneimettelforschung/Drug Res. 41, 773-780.

33. Riederer, P., Lange, K. W., Kornhuber, J., and Danielczyk, W. (1991) Pharmacotoxic psychosis after memantine in Parkinson's disease. Lancet 338, 1022-1023.

34. Rabey, J. M., Nissipeanu, P., and Korczyn, A. D. (1992) Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J. Neural Transm. 4, 277-282.

35. Mueller, A. L., Artman, L. D., Balandrin, M. F., Brady E., Chien Y., Delmar, E. G., et al, (1999) NPS 1506, a novel NMDA receptor antagonist and neuroprotectant. Review of preclinical and clinical studies. Ann. NY Acad. Sci. 890, 450-457.

36. Porter, P. H., and Greenamyre, J. T., (1995) Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J. Neurochem. 64, 614-623.

37. Bresink, I., Danysz, W., Parsons, C. G., and Mutschler, E. (1995) Different binding affinities of NMDA receptor channel blockers in various brain regions—indication of NMDA receptor heterogeneity. Neuropharmacology 34, 533-540.

38. Baumann, M. H., Rothman, R. B., and Ali, S. F. (2000) Comparative neurobiological effects of ibogaine and MK-801 in rats. Drug Alcohol Depend. 59,143-151.

39. Rho, J. M., Donevan, S. D., and Rogawski, M. A. (1994) Mechanism of action of the anticonvulsant felbamate: opposing effects on NMDA and GABA, receptors. Ann. Neurol. 35, 229-234.

40. Popik, P., Layer, R. T., and Skolnick, P. (1995) 100 years of ibogaine:neurochemical and pharmacological actions of a putative anti-addictive drug. Pharmacol. Rev. 47, 235-253.

41. Mash, D. C., Kovera, C. A., Buck, B. E., Norenberg, M. D., Shapshak, P., Hearn, W. L., et al. (1998) Medication development of ibogaine as a pharmacotherapy for drug dependence. Ann. NY Acad. Sci. 844, 274-292.

42. Popik., P., Layer, R. T., Fossom, L. H., Benveniste, M., Geter-Dopuglass, B., Witkin, J. M. et al, (1995) NMDA antagonist properties of the putative anti-addictive drug, ibogaine. J. Pharmacol. Exp. Ther. 275, 753-760.

43. Chen, K., Kokate, T. G., Donevan, S. D., Carroll, F. I., and Rogawski, M. A. (1996) Ibogaine block of the NMDA receptor: in vitro and in vivo studies. Neuropharmacology 35, 423-431.

44. Newman, A. H. (2000) Novel pharmacotherapies for cocaine abuse 1997-2000. Exp. Opin. Ther. Patents 10,1095-1122.

45. Willetts, J., Balster, R. L., and Leander, J. D. (1990) The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol. Sci. 11, 423-428.

46. Kornhuber, J. and Weller, M. (1997) Psychotogenicity and N-methyl-d-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol. Psychiatry 41,135-144.

47. Sveinbjornsdottir, S., Sander, J. W. A. S., Upton, D., Thompson, P. J., Patsalos, P. N., Hirt, D., et al. (1993) The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res. 16, 165-174.

48. Bullock, R. (1995) Strategies for neuroprotection with glutamate antagonists. Extrapolating from evidence taken from the first stroke and head injury studies. Ann. NY Acad. Sci. 765, 272-278.

49. Carter, A. (1994) Many agents that antagonize the NMDA receptor-channel complex in vivo also cause disturbances of motor coordination. J. Pharmacol. Exp. Ther. 269, 573-580.

50. Löscher, W. and Hönack, D. (1991a) Anticonvulsant and behavioral effects of two novel competitive N-methyl-d-aspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindling model of epilepsy. Comparison with MK-801 and carbamazepine. J. Pharmacol. Exp. Ther. 256, 432-440.

51. Löscher, W. and Hönack, D. (1991b) The novel competitive N-methyl-d-aspartate (NMDA) antagonist CGP 37849 preferentially induces phencylidine-like behavioral effects in kindled rats: attenuation by manipulation of dopamine, alpha-1, and serotonin1A receptors. J. Pharmacol. Exp. Ther. 257, 1146-1153.

52. Smith, S. E. and Chapman, A. G. (1993) Acute and chronic anticonvulsant effects of D(-)CPPene in genetically epilepsy-prone rats. Epilepsy Res. 15, 193-199.

53. Willetts, J., Clissold, D. B., Hartman, T. L., Brandsgaard, R. R., Hamilton, G. S., and Ferkany, J. W. (1993) Behavioral pharmacology of NPC 17742, a competitive N-methyl-d-aspartate (NMDA) antagonist. J. Pharmacol. Exp. Ther. 265, 1055-1062.

54. Johnson, J. W. and Ascher, P. (1987) Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325, 529-531.

55. Kleckner, N. W. and Dindeldine, R. (1988) Requirement for glycine in activation of NMDA-receptors expressed in Xeno-pus oocytes. Science 241, 444-449.

56. Mothet, J-P., Parent, A. T., Wolosker, H., Brady, R. O., Jr., Linden, D. J., Ferris, C. D., et al. (2000) d-Serine is an endogenous ligand for the glycine site of the N-Mehtyl-d-aspartate receptor. Proc. Natl.Acad. Sci. USA 97, 4926-4931.

57. Viu, E., Zapata, A., Capdevila, J. et al. (2000) Glycine(B) receptor antagonists and partial agonists prevent memory deficits in inhibitory avoidance learning. Neurobiol. Learn. Mem. 74,146-160.

58. Balster, R. L., Mansbach, R. S., Shelton, K. L., Nicholson, K. L., Grech, D. M., Wiley, J. L., et al. (1995) Behavioural pharmacology of two novel substituted quinoxalinedione glutamate antagonists. Behav. Pharmacol. 6, 577-590.

59. Witkin, J. M., Brave, S., French, D., and Geter-Douglass, B. (1995) Discriminative stimulus effects of R-(+)-3-amino-1-hydroxypyrrolid-2-one, [(+)-HA-966], a partial agonist of the strychnine-insensitive modulatory site of the N-methyl-d-aspartate receptor. J. Pharmacol. Exp. Ther. 275, 1267-1273.

60. Witkin, J. M., Steele T. D., and Sharpe, L. G. (1997) Effects of strychnine-insensitive glycine receptor ligands in rats discriminating either dizocilpine or phencyclidine from saline. J. Pharmacol. Exp. Ther. 280, 46-52.

61. Kotlinska, J. and Bialwa, G. (2000) Memantine and ACPC affect conditioned place preference induced by cocaine in rats. Pol. J. Pharmacol. 52, 179-185.

62. Honer, M., Benke, D., Laube, B., Kuhse, J., Heckendorn, R., Allgeier, H., et al. (1998) Differentiation of glycine antagonist sites of N-methyl-d-aspartate receptor subtypes. J. Biol. Chem. 273, 11,158-11,163.

63. Carling, R. W., Leeson, P. D., Moore, K. W., Smith, J. D., Moyes, C. R., Mawer, I. M., et al. (1993) 3-Nitro-3,4-dihydro-2(1ff)-quinolones. Excitatory amino acid antagonists acting at glycine-site NMDA and (RSJ-a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. J. Med. Chem. 36, 3397-3408.

64. Kloog, Y., Haring, R., and Sokolovsky, M. (1988) Kinetic characterization of the phencylidine-N-methyl-d-aspartate receptor interaction: evidence for a steric blockade of the channel. Biochemistry 27, 843-848.

65. Ascher, P. and Nowak, L. (1987) Electrophysiological studies of NMDA receptors. Trends Neurosci. 10, 284-287.

66. Salt, T. E. (1989) Modulation of NMDA receptor-mediated responses by glycine and d-serine in the rat thalamus in vivo. Brain Res. 481, 403-406.

67. Thomson, A. M., Walker, V. E., and Flynn, D. M. (1989) Glycine enhances NMDA-receptor medicated synaptic potentials in neocortical slices. Nature 338, 422-424.

68. Toth, E. and Lajtha, A. (1986) Antagonism of phencyclidine-induced hyperactivity by glycine in mice. Neurochem. Res. 11, 393-400.

69. Evoniuk, G. E., Hertzman, R. P., and Skolknick, P. (1991) A rapid method for evaluating the behavioral effects of phency-clidine-like dissociative anesthetics in mice. Psychopharmacology 105, 125-128.

70. Contreras, P. (1990) d-Serine antagonized phencyclidine and MK-801-induced stereotyped behavior and ataxia. Neu-ropharmacology 29, 291-293.

71. Tanii, Y., Nishikawa, T., Hashimoto, A., and Takahaski, K. (1991) Stereoselective inhibition by d- and l-alanine of phency-clidine-induced locomotor stimulation in the rat. Brain Res. 563, 281-284.

72. Tanii, Y., Nishikawa, T., Hashimoto, A., and Takahaski, K. (1994) Stereoselective antagonism by enantiomers of alanine and serine of phencyclidine-induced hyperactivity, stereotypy and ataxia. J. Pharmacol. Exp. Ther. 269, 1040-1048.

73. McBain, C. J., and Mayer, M. L. (1994) N-Methyl-d-aspartic acid receptor structure and function. Physiol. Rev. 74, 723-760.

74. Avenet, P., Léonardon, J., Besnard, F., Graham, D., Depoortere, H., and Scatton, B. (1997) Anagonist properties of eliprodil and other NMDA receptor antagonists at rat NR1A/NR2A and NR1A/NR2B receptors expressed in Xenopus oocytes. Neu-rosci. Lett. 223,133-136.

75. Brimecombe, J. C., Boeckman, F. A., and Aizenman, E. (1997) Functional consequences of NR2 subunit composition in single recombinant N-methyl-d-aspartate receptors. Proc. Natl. Acad. Sci. USA 94,11109-11024.

76. Fischer, G., Mutel, V., Trube, G., Malherbe, P., Kew, J. N. C., Mohacsi, E., et al. (1997) Ro 25-6981, a highly potent and selective blocker of N-methyl-d-aspartate receptors containing the NR2B subunit. Characterization in vitro. J. Pharmacol. Exp. Ther. 283, 1285-1292.

77. Tamiz, A. P., Whittemore, E. R., Zhou, Z.-L., Huang, J.-C, Drewe, J. A., Chen, J.-C., et al. (1998) Structure-activity relationships for a series of bis(phenylalkyl) amines: potent subtype-selective inhibitors of N-methyl-d-aspartate receptors. J. Med. Chem. 41, 3499-3506.

78. Mott, D., Doherty, J., Zhang, S., Washburn, M., Fendley, M., Lyuboslavsky, P., et al. (1998) Enhancement of proton inhibition: a novel mechanism for NMDA receptor inhibition by phenylethenolamines. Nature Neurosci. 1, 659-667.

79. Scatton B., Avenet, P., Benavides, J., Carter, C., Duverger, D., Oblin, A., et al. (1994) Neuroprotective potential of the polyamine site-directed NMDA receptor antagonists—ifenprodil and eliprodil, in Direct and Allosteric Control of Glutamate Receptors (Palfreyman, M. G., Reynolds, I. J., and Skolnick, P., eds.), CRC, Boca Raton Fl, pp. 139-154.

80. Duval, D., Roome, N., Gauffeny, C., Nowicki, J. P., and Scatton, B. (1992) SL 82.0715, an NMDA antagonist acting at the polyamine site, does not induce neurotoxic effects on rat cortical neurons. Neurosci. Lett. 137,193-197.

81. Deren-Wesolek, A. and Maj, J. (1993) Central effects of SL 82.0715, an antagonist of polyamine site of the NMDA receptor complex. Pol. J. Pharmacol. 45, 467-480.

82. Harty, T. P. and Rogawski, M. A. (1997) Channel block of NMDA receptors by the anticonvulsant ADCI: studies with cloned NR1a/NR2A and NR1a/NR2B subunits. Soc. Neurosci. Abst. 23, 2165.

83. Harty, T. P. and Rogawski, M. A. (2000) Felbamate block of recombinant N-methyl-d-aspartate receptors: selectivity for the NR2B subunit. Epilepsy Res. 29, 47-55.

84. Donevan, S. D. and McCabe, R. T. (2000) Conantokin G is an NR2B-selective competitive antagonist of N-methyl-d-aspar-tate receptors. Mol. Pharmacol. 58, 614-623.

85. Gallagher, M. J., Huang, H., and Lynch, D. R. (1998) Modulation of the N-methyl-d-aspartate receptor by haloperidol: NR2B-specific interactions. J. Neurochem. 70, 2120-2128.

86. Yamakura, T., Sakimura, K., Mishina, M., and Shimoji, K. (1998) Sensitivity of the N-methyl-d-aspartate receptor channel to butyrophenones is dependent on the e2 subunit. Neuropharmacology 37, 709-717.

87. Mori, H. and Mishina, M. (1995) Structure and function of the NMDA receptor channel. Neuropharmacology 34, 1219-1237.

88. Li, H. and Rogawski, M. A. (1998) GluR5 kainate receptor mediated synaptic transmission in rat basolateral amygdala in vitro. Neuropharmacology 37, 1279-1286.

89. Lerma, J. (1998) Kainate receptors: an interplay between excitatory and inhibitory synapses. FEBS Lett. 430, 100-104.

90. Rodriguez-Moreno, A., Lopez-Garcia, J. C., and Lerma, J. (2000) Two populations of kainate receptors with separate signaling mechanisms in hippocampal interneurons. Proc. Natl. Acad. Sci. 97, 1293-1298.

91. Bleakman, D. and Lodge, D. (1998) Neuropharmacology of AMPA and kainate receptors. Neuropharmacology 37, 1187-1204.

92. Rogawski, M. A. and Donevan, S. D. (1999) AMPA receptors in epilepsy and as targets for antiepileptic drugs, in Jasper's Basic Mechanisms of the Epilepsies: 3rd ed. Advances in Neurologic Vol. 79 (Delgado-Escueta, A. V. Wilson, W. A., Olsen, R. W., and Porter, R. J., eds.), Lippincott Williams & Wilkins, Philadelphia, pp 947-963.

93. Lees, G. J. (2000) Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders. Drugs 59, 33-78.

94. Honoré, T. (1991) Inhibitors of kainate and AMPA ionophore receptors, in: Excitatory Amino Acid Antagonists (Meldrum, B. S., ed.), Blackwell, Oxford, pp. 180-194.

95. Watjen, F., Nielsen, E. O., Drejer, J., and Jensen, L. H. (1993) Isatin oximes—a novel series of bioavailable non-NMDA antagonists. Bioorg. Med. Chem. Lett. 3, 105-106.

96. Nijholt, I., Blank T., Grafelmann, B., Cepok, S., Kugler, H., and Spiess, J. (1999) NS-257, a novel competitive AMPA receptor antagonist, interacts with kainate and NMDA receptors. Brain Res. 821, 374-382.

97. Witkin, J. M. (1993) Blockade of the locomotor stimulant effects of cocaine and methamphetamine by glutamate antagonists. Life Sci. 53, PL405-PL410.

98. Li, Y., Hu, X. T., Berney, T. G., Vartanian, A. J., Stine, C. D., Wolf, M. E., et al. (1999) Both glutamate receptor antagonists and prefrontal cortex lesions prevent induction of cocaine sensitization and associated neuroadaptations. Synapse 34, 169-180.

99. Cornish, J. L. and Kalivas, P. W. (2000) Glutamate neurotransmission in the nucleus accumbens mediates relapse in cocaine addiction. J. Neurosci. 20, 1-5.

100. Ingwersen, S. H., Ohrstrom, J. K., Petersen, P. Drustrup, J., Bruno, L., and Nordholm, L. (1994) Human pharmacokinetics of the neuroprotective agent NBQX. Am. J. Ther. 1, 296-303.

101. Ohmori, J., Sakamoto, S., Kubota, H., Shimizu-Sasamata, M., Okada, M., Kawasaki, S., et al. (1994) 6-(1ff-Imidazol-1-yl)-7-nitro-2,3(1ff,4ff)-quinoxalinedione hydrochloride (YM90K) and related compounds:structure-activity relationships for the AMPA-type non-NMDA receptor. J. Med. Chem. 37, 467-475.

102. Umemura, K., Kondo, K., Ikeda, Y, Teraya, Y., Yoshida, H., Homma. M., et al. (1997) Pharmacokinetics and safety of the novel amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist YM90K in healthy men. J. Clin. Pharmacol. 37, 719-727.

103. Ohmori,J., Shimizu-Sasamata, M., Okada, M., and Sakamoto S. (1997) 8(1ff-Imidazol-1-yl)-7-nitro-4(5ff)-imidazo[1,2-alpha]quinoxalinone and related compounds; synthesis and structure activity relationships for the AMPA-type non-NMDA receptor. J. Med Chem. 40, 2053-2063

104. Ohmori, J., Shimizu-Sasamata, M., Okada, M., and Sakamoto S. (1996) Novel AMPA receptor antagonists: synthesis and structure-activity relationships of 1-hydroxy-7-(1ff-imidazol-1-yl)-6-nitro-2,3(1ff,4ff)-quinoxalinedione and related compounds. J. Med. Chem. 39, 3971-3979.

105. Kohara, A., Okada, M., Tsutsumi, R., Ohno, K., Takahashi, M., Shimizu-Sasamata, M., et al. (1998) In-vitro characterization of YM872, a selective, potent and highly water-soluble alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist. J. Pharm. Pharmacol. 50, 795-801.

106. Takahashi, M., Ni, J. W., Kawasaki-Yatsugi, S., Toya, T., Yatsugi, S. I., Shimizu-Sasamata, M., et al. (1998) YM872, a novel selective alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, reduces brain damage after permanent focal cerebral ischemia in cats. J. Pharmacol. Exp. Ther. 284, 467-473.

107. Kawasaki-Yatsugi, S., Ichiki, C., Yatsugi, S., Takahashi, M., Shimizu-Sasamata, M., Yamaguchi, T., et al. (2000) Neuropro-tective effects of an AMPA receptor antagonist YM872 in a rat transient middle cerebral artery occlusion model. Neu-ropharmacology 39, 211-217.

108. Nishiyama, T., Gyermek, L., Lee, C., Kawasaki-Yatsugi, S., and Yamaguchi, T. (1999) The systemically administered competitive AMPA receptor antagonist, YM872, has analgesic effects on thermal or formalin-induced pain in rats. Adnaesth. Analg. 89, 1534-1537.

109. Schoepp, D. D., Lodge D., Bleakman, D., Leander, J. D., Tizzano, J. P., Wright, R. A., et al. (1995) In vitro and in vivo antagonism of AMPA receptor activation by (3S4aR6R,8aR)-6-[2-(1(2)ff-tetrazole-5-yl)ethyl]-decahydroisoquinoline-3-carboxylic acid. Neuropharmacology 34, 1159-1168.

110. Bleakman, R., Schoepp, D. D., Ballyk, B., Bufton, H., Sharpe, E. F., Thomas, K., et al. (1996) Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)ff-tetrazole-5-yl)ethyl]decahydroisdo-quinoline-3 carboxylic-acid. Mol. Pharmacol. 49, 581-585.

111. Rogawski, M. A., Kurzman, P., Yamaguchi, S., and Li, H. (2000) Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse. Neuropharmacology, 40, 28-35.

112. Carlezon, W. A., Jr., Rasmussen, K., and Nestler, E. J. (1999) AMPA antagonist LY293558 blocks the development, without blocking the expression, of behavioral sensitization to morphine. Synapse 31, 256-262.

113. Kest, B., McLemore, G., Kao, B., and Inturrisi, C. E. (1997) The competitive alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist LY293558 attenuates and reverses analgesic tolerance to morphine but not to delta or kappa opioids. J. Pharmacol. Exp. Ther. 283, 1249-1255.

114. Rasmussen, K., Kendrick, W. T., Kogan J. H., and Aghajanian, G. K. (1996) A selective AMPA antagonist, LY293558, suppresses morphine withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. Neuropsychopharmacology 15, 497-505.

115. Sang, C. N., Hostetter, M. P., Gracely, R. H., Chappell, A. S., Schoepp, D. D., Lee, G., et al. (1998) AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans. Anesthesiology 89, 1060-1067.

116. Mutel, V., Trube, G., Klingelschmidt, A., Messer, J., Bleuel , Z., Humbel U., et al. (1998) Binding characteristics of a potent AMPA receptor antagonist [3H]Ro 48-8587 in rat brain. J. Neurochem. 71, 418-426.

117. Löscher, W., Lehmann, H., Behl, B., Seemann, D., Teschendorf, H. J., Hofmann, H. P., et al. (1999) A new pyrrolyl-quinox-alinedione series of non-NMDA glutamate receptor antagonists: pharmacological characterization and comparison with NBQX and valproate in the kindling model of epilepsy. Eur. J. Neurosci. 11, 250-262.

118. Turski, L., Huth, A., Sheardown, M., McDonald, F., Neuhaus, R., Schneider, H. H., et al. (1998) ZK200775: a phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma. Proc. Natl. Acad. Sci. USA 95,10,960-10,965.

119. Löscher, W., Rundfeldt, C., and Hönack, D. (1993) Low doses of NMDA receptor antagonists synergistically increase the anticonvulsant effect of the AMPA receptor antagonist NBQX in the kindling model of epilepsy. Eur. J. Neurosci. 5, 1545-1550.

120. Löscher, W. (1998) New visions in the pharmacology of anticonvulsion. Eur. J. Pharmacol. 342,1-13.

121. Potschka, H., Löscher, W., Wlaz, P., Behl, B., Hofmann, H. P., Treiber, H. J., et al (1998) LU73068, a new non-NMDA and glycine/NMDA receptor antagonist: pharmacological characterization and comparison with NBQX and L-701,324 in the kindling model of epilepsy. Br. J. Pharmacol. 125,1258-1266.

122. Tarnawa, I., Farkas, S., Berzsenyi, P., Pataki, A., and Andrasi, F. (1989) Electrophysiological studies with a 2,3-benzodi-azepine muscle relaxant: GYKI 52466. Eur. J. Pharmacol. 167, 193-199.

123. Bleakman, D., Ballyk, B. A., Schoepp, D. D., Palmer, A. J., Bath, C. P., Sharpe, E. F., et al. (1996) Activity of 2,3-benzodi-azepines at native rat and recombinant human glutamate receptors in vitro: stereospecificity and selectivity profiles. Neuropharmacology 35, 1689-1702.

124. Donevan, S. D., Yamaguchi, S., and Rogawski, M. A. (1994) Non-N-methyl-d-aspartate receptor antagonism by 3-N-sub-stituted 2,3-benzodiazepines: relationship to anticonvulsant activity. J. Pharmacol. Exp. Ther. 271, 25-29.

125. Donevan, S. D. and Rogawski, M. A. (1993) GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron 10, 51-59.

126. Zorumski, C. F., Yamada, K. A., Price, M. T., and Olney, J. W. (1993) A benzodiazepine recognition site associated with the non-NMDA glutamate receptor. Neuron 10: 61-67.

127. Tarnawa, I. and Vizi, E. S. (1998) 2,3-Benzodiazepine AMPA antagonists. Restor. Neurol. Neurosurg. 13, 41-57.

128. Yamaguchi, S., Donevan, S. D., and Rogawski, M. A. (1993) Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBQX in maximal electroshock and chemoconvulsant models, Epilepsy Res. 15, 179-184.

129. Lodge, D., Bond, A., O'Neill, M. J., Hicks, C. A., and Jones, M. G. (1996) Stereoselective effects of 2,3-benzodiazepines in vivo: electrophysiology and neuroprotection studies. Neuropharmacology 35, 1681-1688.

130. Abraham, G., Solyom, S., Csuzdi, E., Berzsenyi, P., Ling, I., Tarnawa, I., et al. (2000) New non competitive AMPA antagonists. Bioorg. Med. Chem. 8, 2127-2143.

131. Pelletier, J. C., Hesson, D. P., Jones, K. A., and Costa, A. M. (1996) Substituted 1,2-dihydrophthalazines: potent, selective, and noncompetitive inhibitors of the AMPA receptor. J. Med. Chem. 39, 343-346

132. Pei, X.-F., Sturgess, M. A., Valenzuela, C. F., and Maccecchini, M.-L. (1999) Allosteric modulators of the AMPA recep-tor:novel 6-substituted dihydrophthalazines. Bioorg. Med. Chem. Lett. 9, 539-542.

133. Grasso, S., De Sarro, G., De Sarro, A., Micale, N., Zappala, M., Puja, G., et al (2000) Synthesis and anticonvulsant activity of novel and potent 6,7-methylenedioxyphthalazin-1(2ff)-ones. J. Med. Chem. 43, 2851-2859.

134. Chenard, B. L., Menniti, F. S., Pagnozzi, M. J., Shenk, K. d., Ewing, F. E., and Welch, W. M. (2000) Methaqualone derivatives are potent noncompetitive AMPA receptor antagonists. Bioorg. Med. Chem. Lett. 10,1203-1205.

135. Yamada, K. A. (1998) Modulating excitatory synaptic neurotransmission: potential treatment for neurological disease? Neurobiol. Dis. 5, 67-80.

136. Zivkovic, I., Thompson, D. M., Bertolino, M., Uzunov, D., DiBella, M., Costa, E., et al. (1957) 7-Chloro-3-methyl-3-4-dihydro-2ff-1,2,4 benzothiadiazine S,S-dioxide (IDRA 21): a benzothiadiazine derivative that enhances cognition by attenuating dl-alpha-amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid (AMPA) receptor desensitization. J. Pharmacol. Exp. Ther. 272, 300-309.

137. Thompson, D. M., Guidotti, A., DiBella, M., and Costa, E. (1995) 7-Chloro-3-methyl-3,4-dihydro-2ff-1-2,4-benzothiadi-azine S,S-dioxide (IDRA 21), a congener of aniracetam, potently abates pharmacologically induced cognitive impairments in patas monkeys. Proc. Natl. Acad. Sci. USA 92, 7667-7671.

138. Hampson, R. E., Rogers, G., Lynch, G., and Deadwyler, S. A. (1998) Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance. J. Neurosci. 18, 2740-2747.

139. Hampson, R. E., Rogers, G., Lynch, G., and Deadwyler, S. A. (1998b) Facilitative effects of the ampakine CX516 on short-term memory in rats: correlations with hippocampal neuronal activity. J. Neurosci. 18, 2748-2763.

140. Ingvar, M., Ambros-Ingerson, J., Davis, M., Granger, R., Kessler, M., Rogers, G. A., et al. (1997) Enhancement by an ampakine of memory encoding in humans. Exp. Neurol. 146, 553-559.

141. Lynch, G., Granger, R., Ambros-Ingerson, J., Davis, C. M., Kessler, M., and Schehr, R. (1997) Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans. Exp. Neurol. 145, 89-92.

142. Meador-Woodruff, J. H. and Healy, D. J. (2000) Glutamate receptor expression in schizophrenic brain. Brain Res. Brain. Res. Rev. 31, 288-294.

143. Johnson, S. A., Luu, N. T., Herbst, T. A., Knapp, R., Lutz, D., Arai, A., et al. (1999) Synergistic interactions between ampakines and antipsychotic drugs. J. Pharmacol. Exp. Ther. 289, 392-397.

144. Bowie, D. and Smart, T. G. (1993) Thiocyanate ions selectively antagonize AMPA-evoked responses in Xenopus laevis oocytes injected with chick brain mRNA. Neurosci. Lett. 121, 68-72.

145. Donevan, S. D. and Rogawski, M. A. (1998) Allosteric regulation of AMPA receptors SCN- and cyclothiazide at a common modulatory site distinct from that of 2,3-benzodiazepines. Neuroscience 87, 615-629.

146. Chittajallu, R., Braithwaite, S. P., Clarke, V. R., and Henley, J. M. (1999) Kainate receptors: subunits, synaptic localization and function. Trends Pharmacol. Sci. 20, 26-35.

147. Frerking, M. and Nicoll, R. A. (2000) Synaptic kainate receptors. Curr. Opin. Neurobiol. 10, 342-351.

148. Johansen, T. H., Drejer, J., Watjen, F., and Nielsen, E. O. (1993) A novel non-NMDA receptor antagonist shows selective displacement of low-affinity [3H]kainate binding. Eur. J. Pharmacol. 246, 195-204.

149. Verdoorn, T. A., Johansen, T. H., Drejer, J., and Nielsen, E. O. (1994) Selective block of recombinant glur6 receptors by NS-102, a novel non-NMDA, receptor antagonist. Eur. J. Pharmacol. 269, 43-49.

150. Paternain, A. V., Morales, M., and Lerma, J. (1995) Selective antagonism of AMPA receptors unmasks kainate receptor-mediated responses in hippocampal neurons. Neuron 14,185-189.

151. O'Neill, M. J., Bogaert, L., Hicks, C. A., Bond , A., Ward, M. A., Ebinger. G., et al. (2000) LY377770, a novel iGlu5 Kainate receptor antagonist with neuroprotective effects in global and focal cerebral ischaemia. Neuropharmacology 39, 1575-1588.

152. O'Neill, M. J., Bond, A., Ornstein, P. L., Ward, M. A., Hicks, C. A., Hoo, K., et al. (1998) Decahydroisoquinolines:novel competitive AMPA/Kainate antagonists with neuroprotective effects in global cerebral ischaemia. Neuropharmacology 37, 1211-1222.

153. Vignes, M. and Collingridge, G. L. (1997) The synaptic activation of kainate receptors. Nature 388, 179-182.

154. Clarke, V. R. J., Ballyk, B. A., Hoo, K. H., Mandelzys, A., Pellizzari, A., Bath, C. P., et al (1997) A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission. Nature 389, 599-603.

155. Pemberton, K. E., Belcher, S. M., Ripellino, J. A., and Howe, J. R. (1998) High-affinity kainate-type ion channels in rat cerebellar granule cells. J. Physiol. 510, 401-420.

156. Li, P., Wilding, T., Kim, S. J., Calejesan, A. A., Huettner, J. E., and Zhuo, M. (1999) Kainate receptor-mediated sensory synaptic transmission in mammalian spinal cord. Nature 397, 161-164.

157. Simmons R. M. A., Li, D. L., Hoo, K. H., Deverill, M., Omstein, P. L., and Iyengar, S. (1998) Kainate GluR5 receptor subtype mediates the nociceptive response to formalin in the rat. Neuropharmacology 37, 25-36.

158. Sailer, A., Swanson , G. T., Perez-Otano, I, O'Leary, L., Malkmus, S. A., Dyck, R. H., et al. (1999) Generation and analysis of GluR5(Q636R) kainate receptor mutant mice. J. Neurosci. 19, 8757-8764.

159. Li, H. and Rogawski, M. A. (1999) Kainate receptor mediated heterosynaptic facilitation in the amygdala, Soc. Neurosci. Abst. 25, 974.

160. Cartmell, J. and Schoepp, D. D. (2000) Regulation of neurotransmitter release by metabotropic glutamate receptors. J. Neu-rochem. 75, 889-907.

161. Conn, P. J. and Pin, J.-P. (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev. Pharmacol. Toxicol. 37, 205-237.

162. Anwyl, R. (1999) Metabotropic glutamate receptors: electrophysiological properties and role in placticity. Brain Res. Rev. 29, 83-120.

163. Bordi, F. and Ugolini, A. (1999) Group I metabotropic glutamate receptors: implications for brain diseases. Prog. Neuro-biol. 59, 55-79.

164. Schoepp, D. D., Jane, D. E., and Monn, J. A. (1999) Pharmacological agents acting at subtypes of metabotropic glutamate receptors, Neuropharmacology 38, 1431-1476.

165. Monn, J. A. and Schoepp, D. D. (2000) Metabotropic glutamate receptor modulators: recent advances and therapeutic potential. Annu. Rep. Med. Chem. 35, 1-10.

166. Varney, M. A. and Suto, C. M. (2000) Discovery of subtype-selective metabotropic glutamate receptor ligands using functional HTS assays. Drug Discov. Today 1(HTS Suppl.), 20-26.

167. Gasparini, F., Inderbitzin, W., Francotte, E., Lecis, G., Richert, P., Dragic, Z., et al. (2000) (+)-4-Phosphonophenylglycine (PPG) a new group III selective metabotropic glutamate receptor agonist. Bioorg. Med. Chem. Lett. 10, 1241-1244.

168. Moghaddam, B. and Adams, B. W. (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281, 1349-1352.

169. Cartmell, J., Monn, J. A., and Schoepp, D. D. (1999) The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J. Pharmacol. Exp. Ther. 291, 161-170.

170. Helton, D. R., Tizzano, J. P., Monn, J. A., Schoepp, D. D., and Kallman, M. J. (1997) LY354740: a potent, orally active, highly selective metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal. Neurophar-macology 36, 1511-1516.

171. Vandergriff, B. C. and Rasmussen, K. (1999) The selective mGlu2/3 receptor agonist LY354740 attenuates morphine-withdrawal-induced activation of locus coerulus neurons and behavioral signs of morphine withdrawal. Neuropharmacology 38, 217-222.

172. Popik, P., Kozela, E., and Pilc, A. (2000) Selective agonist of group II glutamate metabotropic receptors, LY354740, inhibits tolerance to analgesic effects of morphine in mice. Br. J. Pharmacol. 130,1425-1431.

173. Chapman, A. G., Nanan, K., Williams, M., and Meldrum, B. S. (2000) Anticonvulsant activity of two metabotropic glutamate Group I antagonists selective for mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine (SIB 1893). Neuropharmacology 39,1567-1574.

174. Neugebauer, V., Zinebi, F., Russell, R., Gallagher, J. P., and Shinnick-Gallagher, P. (2000) Cocaine and kindling alter the sensitivity of group II and III metabotropic glutamate receptors in the central amygdala. J. Neurophysiol. 84, 759-770.

175. Stefani, A., Spadoni, F., and Benardi, G. (1997) Differential inhibition by riluzole, lamotrigine and phenytoin of sodium and calcium currents in cortical neurones:implicaitons for neuroprotective strategies. Exp. Neurol. 147, 115-122.

176. Zhu, W. and Rogawski, M. A. (1999) Zonisamide depresses excitatory synaptic transmission by a presynaptic action. Epilepsia 40(Suppl. 7), 244.

177. Cunningham, M. O. and Jones, R. S. G. (2000) The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology 39, 2139-2146.

178. Cunningham, M. O., Dhillon, A., Wood, S. J., and Jones, R. S. G. (2000) Reciprocal modulation of glutamate and GABA release may underlie the anticonvulsant effect of phenytoin. Neuroscinece 95, 343-351.

179. Waldmeier, P. C., Baumann, P. A., Wicki, P., Feldtrauer, J.-J., Stierlin, C., and Schmutz, M. (1995) Similar potency of car-bamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Neurology 45,1907-1913.

180. Snyder, S. H. (1992) Nitric Oxide, first in a new class of neurotransmitters. Science 257, 494-496.

181. Semba, J., Wantanabe, H., Suhara, T., and Akanuma, N. (2000) Neonatal treatment with l-Name (NG-nitro-l-arginine methylester) attenuates stereotyped behavior induced by acute methamphetamine but not development of behavioral sensi-tization to methamphetamine. Prog. Neuro-Pyschopharmacol. Biol. Psychiatry 24, 1017-1023.

182. Haracz, J. L., MacDonall, J. S., and Sircar, R. (1997) Effects of nitric oxide synthase inhibitors on cocaine sensitization. Brain Res. 746,183-189.

183. Pulvirenti, L., Balducci, C., and Koob, G. F. (1996) Inhibition of nitric oxide synthesis reduces intravenous cocaine self-administration in the rat. Neuropharmacology 35, 1811-1814.

184. Itzhak, Y. (1995) Cocaine kindling in mice. Responses to N-methyl-d,l-aspartate (NMDLA) and l-arginine. Mol. Neuro-biol. 11, 217-222.

185. Johansson, C., Deveney, A. M., Reif, D., and Jackson, D. M. (1999) The neuronal selective nitric oxide inhibitor AR-R 17477, blocks some effects of phencyclidine, while having no observable behavioural effects when given alone. Pharmacol. Toxicol. 84, 226-233.

186. Wiley, J. L., Harvey, S. A., and Balster, R. L. (1999) Nitric oxide synthase inhibitors do not substitute in rats trained to discriminate phencyclidine from saline. Eur. J. Pharmacol. 367, 7-11.

187. Neale, J. H., Bzdega, T., and Wroblewska, B. (2000) N-Acetylaspartylglutamate: the most abundant peptide neurotransmit-ter in the mammalian central nervous system. J. Neurochem. 75, 443-452.

188. Wroblewska, B., Wroblewski, J. T., Pshenichkin, S., Surin, A., Sullivan, S. E., and Neale, J. H. (1997) NAAG selectively activates mGluR3 receptors in transfected cells. J. Neurochem. 69, 174-181.

189. Jackson, P. F., Cole, D. C., Slusher, B. S., Stetz, S. L., Ross, L. E., Donazanti, B. A., et al. (1996) Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated a-linked acidic dipeptidase. J. Med. Chem. 39, 619-622.

190. Slusher, B. S, Vornov, J. J., Thomas, A. G., Hurn, P. D., Harukuni, I., Bhardwaj, A., et al. (1999) Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nature Med. 5,1396-1402.

191. Shippenberg, T. S., Rea, W., and Slusher, B. S. (2000) Modulation of behavioral sensitization to cocaine by NAALADase inhibition. Synapse, 38, 161-166.

192. Witkin, J. M., Gasior, M., Zapata, A., Slusher, B. S., and Shippenberg, T. S. (2000) Inhibition of NAALAdase: a novel strategy for preventing sensitization to convulsant stimuli. FASEB J. 14, A1414.

193. Nestler, E. J., Berhow, M. T., and Brodkin, E. S. (1996) Molecular mechanisms of drug addiction: adaptations in signal transduction pathways. Mol. Psychiatry 1, 190-199.

194. Skolnick, P. (1999) Antidepressants for the new millennium. Eur. J. Pharmacol. 375, 31-40.

195. Brandolin, C., Sanna, A., De Bernardi, M. A., Follesa, P., Brooker, G., and Mocchetti, I. (1998) Brain-derived neurotrophic factor and basic fibroblast growth factor downregulate NMDA receptor function in cerebellar granule cells. J. Neurosci. 18, 7953-7961.

195. Regier, D. A., Farmer, M. E., Rae, D. S., Locke, B. Z., Keith , S. K., Judd, L. L., et al. (1990) Comorbidity of mental disorders with alcohol and other drug abuse. J. Am. Med. Assoc. 264, 2511-2518.

Natural Detox

Natural Detox

Are you looking for a full total body detox? If so, then you might want to try a 10 day detox or some refer to it as the 2-week detox. A 10-day detox is a full body detox that usually means taking several different steps to reach your total body transformation. It might involve a change in diet, exercise and more.

Get My Free Ebook


Post a comment